Nuveen LLC Makes New Investment in Design Therapeutics, Inc. $DSGN

Key Points

• Nuveen LLC has made a new investment of approximately $568,000 in Design Therapeutics, acquiring 147,228 shares, which constitutes 0.26% of the company.
• Other institutional investors have also increased their stakes in Design Therapeutics, raising the collective ownership by hedge funds and institutional investors to 56.64%.
• Design Therapeutics reported a quarterly loss of ($0.34) earnings per share, which was below analysts' expectations of ($0.32).

Nuveen LLC bought a new stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 147,228 shares of the company's stock, valued at approximately $568,000. Nuveen LLC owned 0.26% of Design Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of DSGN. ProShare Advisors LLC bought a new position in shares of Design Therapeutics during the 4th quarter valued at approximately $71,000. Wells Fargo & Company MN lifted its stake in shares of Design Therapeutics by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 18,428 shares of the company's stock valued at $114,000 after buying an additional 4,013 shares in the last quarter. Palumbo Wealth Management LLC lifted its stake in shares of Design Therapeutics by 6.5% during the 1st quarter. Palumbo Wealth Management LLC now owns 58,278 shares of the company's stock valued at $225,000 after buying an additional 3,582 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Design Therapeutics during the 4th quarter valued at approximately $249,000. Finally, Barclays PLC lifted its stake in shares of Design Therapeutics by 7.2% during the 4th quarter. Barclays PLC now owns 103,571 shares of the company's stock valued at $639,000 after buying an additional 6,936 shares in the last quarter. 56.64% of the stock is owned by institutional investors.

Design Therapeutics Trading Up 5.7%

Shares of DSGN stock traded up $0.33 during trading on Tuesday, reaching $6.15. 20,368 shares of the company's stock traded hands, compared to its average volume of 136,794. The company has a market capitalization of $350.24 million, a P/E ratio of -5.49 and a beta of 1.61. The firm's 50-day moving average is $4.59 and its 200 day moving average is $4.20. Design Therapeutics, Inc. has a 1 year low of $2.60 and a 1 year high of $7.77.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.02). As a group, sell-side analysts predict that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.